

EA SYMPOSIUM
DV 2026



ATHENS, GREECE
7 - 9 MAY



Industry sessions programme booklet



Table of contents

Thursday, 7 May 2026	5
Friday, 8 May 2026	7









Discover the official industry sessions programmes of EADV Symposium 2026 in Athens, Greece.

The satellite symposia will offer a unique opportunity to connect with key thought leaders, access information on emerging science, new products and innovative approaches on a wide range of current medical topics.

As a true platform for collaboration and progress, the EADV would like to thank all the sponsors for providing additional educational opportunities during the EADV Symposium 2026.

Four satellite symposia are organised between 7 and 8 May 2026.

Satellite symposia overview

<p>Expert speakers will explore the mechanisms behind chronic inflammation, discuss how dual inhibition of IL-17A and IL-17F may achieve inflammatory control, and highlight key clinical data alongside real-world evidence. This symposium is intended for healthcare professionals only.</p>	 <p>Inspired by patients. Driven by science.</p>
<p>Is your management strategy keeping pace with the changing needs of your patients with atopic dermatitis? Join our faculty as they discuss real-life challenges through the lens of the latest clinical data. Take control of your learning by selecting clinical challenges that are most relevant to you.</p>	
<p>Expert-led Medical Symposium (Sponsored by Takeda)</p>	
<p>Expert faculty will discuss the role of sebum and androgen signalling in acne pathogenesis, addressing unmet clinical needs and current evidence. The symposium will highlight clinical insights into topical androgen receptor inhibition and its implications for everyday practice.</p>	 <p>glenmark A new way for a new world</p>



Programme at a glance

	Skalkotas Hall	Banqueting Hall
Thursday, 7 May 2026		
	SAT 01	SAT 02
12:45 – 13:45	Takeda Pharmaceuticals (Psoriasis)	Glenmark Pharmaceuticals Europe Ltd., U.K. (Acne Vulgaris, Topical Androgen Receptor Inhibition)
Friday, 8 May 2026		
	SAT 03	SAT 04
12:45 – 13:45	UCB (Psoriasis / Hidradenitis suppurativa HS)	Pfizer (Atopic Dermatitis)

HCP only and Non Members (INDUSTRY)

Satellite symposia programme and faculty

The Industry Session organiser is solely responsible for keeping all its Industry Session activities compliant with all relevant laws and regulations. EADV is not involved with or has any control over the content, quality, organisation, operation, or scientific integrity of the activity and materials provided by the industries. EADV is not involved in the selection of speakers, moderators, and other faculty.

Access to satellite symposia

As a multidisciplinary audience will be attending the EADV Symposium 2026, please make sure to select the right category: Healthcare Professionals (HCPs) or Non-Healthcare Professionals (NON-HCPs), during the registration process.

Access to any Industry Sessions where data or research on prescription medicines is presented will be limited to Healthcare Professionals (HCPs) and Non Members (INDUSTRY).

Industry Session organisers may limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the Industry Session.





Thursday, 7 May 2026

Session type: [Satellite Symposium](#)
 Room: [Skalkotas Hall](#)
 Access: [HCP and Non Member \(INDUSTRY\)](#)
 Time: [12:45 – 13:45](#)



SAT 01		<p>Is Oral Therapy the Future? Innovations That May Redefine Psoriasis Care Chair: Electra Nicolaidou (Athens, Greece)</p>
SAT 01.01	12:45	<p>Is Oral Therapy the Future? Innovations That May Redefine Psoriasis Care Electra Nicolaidou (Athens, Greece) Melinda Gooderham (Peterborough, Canada) Nina Magnolo (Münster, Germany)</p>



Thursday, 7 May 2026

Session type: [Satellite Symposium](#)

Room: [Banqueting Hall](#)

Access: [HCP and Non Member \(INDUSTRY\)](#)

Time: [12:45 – 13:45](#)



Glenmark Pharmaceuticals Europe
Ltd., U.K.

SAT 02		Targeting Sebum and Androgen Signalling in Acne Vulgaris: Unmet Needs, Emerging Evidence, and Clinical Implications
SAT 02.01	12:45	Persistent Acne, Persistent Gaps: Why Sebum Remains the Missing Therapeutic Target Yolanda Gilaberte (Zaragoza, Spain)
SAT 02.02	13:10	A New Approach to Sebum Control: Early Clinical Insights into Topical Androgen Receptor Inhibition (Clascoterone) ▼ Anthony Bewley (London, United Kingdom)
SAT 02.03	13:35	Q&A Yolanda Gilaberte (Zaragoza, Spain) Anthony Bewley (London, United Kingdom)



Friday, 8 May 2026

Session type: [Satellite Symposium](#)

Room: [Skalkotas Hall](#)

Access: [HCP and Non Member \(INDUSTRY\)](#)

Time: 12:45 – 13:45



Inspired by **patients**.
Driven by **science**.

UCB

SAT 03		Inflammation unlocked: dual IL-17A and IL-17F inhibition in HS and psoriasis Chair: Alexandros J. Stratigos (Athens, Greece)
SAT 03.01	12:45	Welcome and introductions Alexandros J. Stratigos (Athens, Greece)
SAT 03.02	12:48	Understanding bimekizumab: how does IL-17A and IL-17F inhibition offer inflammation control? Alexandros J. Stratigos (Athens, Greece)
SAT 03.03	13:03	Controlling inflammation in psoriasis: how can we intervene with bimekizumab? Zoe Apalla (Thessaloniki, Greece)
SAT 03.04	13:18	Capturing the window of opportunity: how does bimekizumab impact clinical response in HS? Farida Benhadou (Brussels, Belgium)
SAT 03.05	13:33	Audience Q&A Alexandros J. Stratigos (Athens, Greece) Zoe Apalla (Thessaloniki, Greece) Farida Benhadou (Brussels, Belgium)
SAT 03.06	13:43	Meeting close Alexandros J. Stratigos (Athens, Greece)

A UCB symposium during EADV Spring 2026

Inflammation unlocked: dual IL-17A and IL-17F inhibition in HS and psoriasis

Join leading dermatology experts as they discuss how modulating the IL-17 axis may optimise inflammatory control and highlight emerging clinical and real-world evidence on the impact of bimekizumab▼ in hidradenitis suppurativa (HS) and psoriasis.

 Friday, 8th May 2026, 12:45–13:45 (EEST)

 Skalkotas Hall, Megaron, Athens

Expert speakers



Prof Alexandros J. Stratigos
University of Athens,
Greece



Prof Zoe Apalla
Aristotle University of Thessaloniki,
Greece



Prof Farida Benhadou
Erasmus Hospital,
Belgium

Agenda

Session

Welcome and introductions

Understanding bimekizumab: how does IL-17A and IL-17F inhibition offer inflammation control?

Controlling inflammation in psoriasis: how can we intervene with bimekizumab?

Capturing the window of opportunity: how does bimekizumab impact clinical response in HS?

Audience Q&A

Meeting close

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via national reporting systems. Please refer to the Summary of Product Characteristics, available at: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf.



Friday, 8 May 2026

Session type: [Satellite Symposium](#)

Room [Banqueting Hall](#)

Access: [HCP and Non Member \(INDUSTRY\)](#)

Time: [12:45 – 13:45](#)



SAT 04		ADapting to Atopic Dermatitis Challenges in Your Practice Chair: Alexander Zink (Munich, Germany) Co-Chair: Maria-Angeliki Gkini (London, United Kingdom)
SAT 04.01	12:45	Welcome and Introduction Alexander Zink (Munich, Germany) Maria-Angeliki Gkini (London, United Kingdom)
SAT 04.02	12:55	Clinical Challenges – Adapting Management Approach for Specific Patient Scenarios Maria-Angeliki Gkini (London, United Kingdom) Alexander Zink (Munich, Germany)
SAT 04.03	13:35	Summary and Audience Questions Alexander Zink (Munich, Germany) Maria-Angeliki Gkini (London, United Kingdom)